Compare AP & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AP | ICCM |
|---|---|---|
| Founded | 1929 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Fluid Controls | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 45.5M |
| IPO Year | N/A | N/A |
| Metric | AP | ICCM |
|---|---|---|
| Price | $2.89 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 222.5K | ★ 403.0K |
| Earning Date | 11-12-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $426,314,000.00 | $2,975,000.00 |
| Revenue This Year | N/A | $13.67 |
| Revenue Next Year | N/A | $38.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.20 | N/A |
| 52 Week Low | $1.75 | $0.59 |
| 52 Week High | $3.99 | $1.66 |
| Indicator | AP | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 64.65 | 41.99 |
| Support Level | $2.46 | $0.67 |
| Resistance Level | $2.95 | $0.72 |
| Average True Range (ATR) | 0.27 | 0.05 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 76.29 | 62.50 |
Ampco-Pittsburgh Corp is manufacturing and selling engineered, specialty metal products and customized equipment. It operates in two business segments namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, and other metals whereas, the Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, and Buffalo Pumps. The company generates a majority of its revenue from the Forged and Cast Engineered Products segment. It has a business presence in the United States and other countries.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.